- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01686165
Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients With Relapsed Aggressive High-Risk Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To document the complete response rate and overall response for patients with relapsed aggressive high-risk non-Hodgkin's lymphoma treated with two cycles PXD-101 followed by one cycle of Zevalin.
SECONDARY OBJECTIVES:
I. To estimate 2-year progression-free survival in patients with relapsed aggressive high-risk non-Hodgkin's lymphoma treated with two cycles PXD-101 followed by one cycle of Zevalin.
II. To evaluate the toxicity of two cycles PXD-101 and one cycle of Zevalin in patients with relapsed aggressive high-risk non-Hodgkin's lymphoma.
OUTLINE:
Patients receive belinostat intravenously (IV) over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724-5024
- University of Arizona Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Biopsy confirmed, CD20 positive diffuse large B-cell lymphoma, primary mediastinal b-cell lymphoma, mantel cell lymphoma, transformed indolent lymphoma, high grade-B-cell lymphoma; AND bone marrow must show =< 20% CD20+ B-cells with >= 15% cellularity within 42 days of study registration
- Any stage disease
Patients must have been previously treated:
- >= 3rd line if bone marrow transplant (BMT) candidate OR
- >= 2nd line if not BMT candidate OR
- >= 2nd relapse for BMT candidate OR
- >= 1st relapse for non- BMT candidate
- Must have a diagnostic quality CT scan of the chest, abdomen and pelvis OR baseline PET-CT scan performed within 28 days prior to registration
- Must have bidimensionally measurable disease with lesions at least 1.5 cm in one dimension ALL measurable disease must be assessed within 28 days of registration
- To determine prior drug regimens: radiation therapy counts as 1 treatment, BMT including induction counts as one treatment, radioimmunotherapy is not considered a chemotherapy regimen, rituximab alone is not considered a treatment; all prior therapy must have been completed at least 30 days prior to registration; patients should not have taken valproic acid, or any other histone deacetylase inhibitor (eg., vorinostat, romidepsin), for at least 30 days prior to registration; patients must have recovered from any toxicities related to therapies prior to registration
- No clinical evidence of CNS involvement by lymphoma, any lab (eg., LDH or radiographic tests performed to access CNS involvement must be negative and must be performed within 42 days prior to registration
- Unilateral or bilateral bone marrow biopsy performed within 42 days prior to registration
- Life expectancy of greater than 3 months
- Karnofsky performance status >= 60%
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- AST (SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal
- Total bilirubin =< 1.5 X institutional upper limit of normal (unless associated with Gilbert's syndrome)
- Serum creatinine < 2 x institutional upper limit of normal OR
- Measured creatinine clearance >= 60 mL/min
- LDH < 1.50 X institutional upper limit of normal
- EKG with no significant abnormalities within 28 days prior to registration
- Women of child-bearing potential and men must agree to use adequate contraception
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 30 days (6 weeks for nitrosoureas or mitomycin C) prior to study screening or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
- Prior radioimmunotherapy
- Pregnant or nursing
- Clinical evidence of CNS involvement by lymphoma
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD-101 or Zevalin or other agents used in the study
- Concomitant medication that may cause Torsade de Pointes, i.e. prolongation of the QT interval > 500 msec
- Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, congestive heart failure related to primary cardiac disease, any condition requiring anti-arrhythmic therapy, ischemic or valvular heart disease, or a myocardial infarction within the past 6 months
- Current long QT syndrome or baseline prolongation of QT/QTcF interval, i.e. demonstration of a QTcF interval > 450 msec
- Clinical evidence of severe peripheral vascular disease, diabetic ulcers or venous stasis ulcers, or history of deep venous or arterial thrombosis within 3 months prior to screening
- Known to be human immunodeficiency virus (HIV) positive or with known acquired immunodeficiency syndrome (AIDS) syndrome
- Patients may not be receiving any other investigational agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Belinostat Yttrium Ibritumomab Tiuxetan
Patients receive belinostat IV over 30-60 minutes on days 1-5.
Treatment with belinostat repeats every 21 days for 2 courses.
Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50.
Treatment continues in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response Rate
Time Frame: Up to 5 years
|
To document the complete response rate for patients with relapsed aggressive high-risk non-Hodgkin's lymphoma (NHL) treated with two cycles PXD-101 followed by one cycle of the Zevalin regimen.
|
Up to 5 years
|
Overall Response
Time Frame: Up to 5 years
|
To document the overall response for patients with relapsed aggressive high-risk non-Hodgkin's lymphoma (NHL) treated with two cycles PXD-101 followed by one cycle of the Zevalin regimen.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival
Time Frame: 2 years
|
Will be estimated using a Kaplan-Meier estimate.
The observed 2-year progression-free survival rate will be estimated (with a 95% confidence interval) from the Kaplan-Meier curve.
|
2 years
|
Occurrence of Adverse Events and Serious Adverse Events
Time Frame: Up to 30 days after patient receives last dose of study drug
|
The proportion of patients with a given adverse event will be tabulated and the 95% confidence interval computed.
|
Up to 30 days after patient receives last dose of study drug
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Lymphoma, B-Cell
- Lymphoma, T-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Recurrence
- Lymphoma, Non-Hodgkin
- Lymphoma, Mantle-Cell
- Lymphoma, Large-Cell, Anaplastic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Histone Deacetylase Inhibitors
- Rituximab
- Antibodies, Monoclonal
- Belinostat
Other Study ID Numbers
- 12-0288-04
- P30CA023074 (U.S. NIH Grant/Contract)
- NCI-2012-01131 (Other Identifier: CTRP (Clinical Trial Reporting Program))
- 1200000288 (Other Identifier: UofA IRB #)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Adult Diffuse Large Cell Lymphoma
-
National Cancer Institute (NCI)CompletedRecurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Adult Diffuse Large Cell LymphomaCanada
-
Xinqiao Hospital of ChongqingXuzhou Medical University; Shanghai Changzheng Hospital; Hrain Biotechnology...UnknownRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III Follicular Lymphoma | Stage...China
-
National Cancer Institute (NCI)CompletedRecurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Anaplastic Large Cell LymphomaUnited States
-
Case Comprehensive Cancer CenterActive, not recruitingStage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell LymphomaUnited States
-
Sunnybrook Health Sciences CentreMerck Sharp & Dohme LLC; ImmunoVaccine Technologies, Inc. (IMV Inc.)CompletedRecurrent | Adult Diffuse Large Cell Lymphoma | Adult Refractory Diffuse Large B-Cell LymphomaCanada
-
Xinqiao Hospital of ChongqingXuzhou Medical UniversityUnknownRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III/IV Adult Diffuse Large Cell Lymphoma | Stage III/IV Follicular Lymphoma | Stage III/IV Mantle Cell LymphomaChina
-
University of NebraskaNational Cancer Institute (NCI); Genta IncorporatedTerminatedStage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell LymphomaUnited States
-
Fox Chase Cancer CenterGenentech, Inc.WithdrawnStage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell LymphomaUnited States
Clinical Trials on rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States